We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Saliva Culture Superior to Neonate Molecular Screening for CMV

By LabMedica International staff writers
Posted on 17 May 2010
A molecular screening test, using heel-prick blood, was not consistently sensitive enough to detect a congenitally transmitted viral infection in neonate blood samples. More...
The samples collected on filter paper are routinely used to test for metabolic and genetic diseases.

The test using real-time polymerase chain reactions (RT-PCR) on dried blood samples (DBS) were compared with saliva culture methods to detect Cytomegalovirus (CMV). The key feature of the RT-PCR procedure is that the amplified DNA is detected as the reaction progresses in real time rather than at the end of the process. The common methods for detection of products in real-time PCR use either nonspecific fluorescent dyes that intercalate with any double-stranded DNA, or sequence-specific DNA probes consisting of oligonucleotides that are labeled with a fluorescent reporter. Single-primer and two-primer RT-PCR systems were used to detect the fluorescent copies of the CMV DNA. The results were published online on April 2010 in the Journal of the American Medical Association (JAMA).


The samples were collected from infants born at seven United States medical centers as part of the National Institute on Deafness and Other Communication Disorders' CMV and Hearing Multicenter Screening (CHIMES) Study (NIDCD; Bethesda, MD, USA). Blood samples taken by heel pricks from neonates are routinely tested for such diseases as hyperthyroidism and sickle cell anemia and could therefore also be used in this study. As CMV infection is a leading cause of sensorineural hearing loss, both of which may be unapparent in the newborn, and at present, the only way to detect the virus is the labor-intensive tissue culture method.

The lead team at the University of Alabama at Birmingham Hospital (Birmingham, AL, USA), tested the diagnostic accuracy of the RT-PCR system for CMV in 20,448 babies. The saliva culture method detected 91/92 that were confirmed to have congenital CMV infection. The single primer RT-PCR was used on 11,422 samples could only detect 17/60 confirmed cases, while the 2-primer set found only 11 positives from the 32 proven cases of the 9,026 samples screened.

In the United States there are an estimated 20,000 to 40,000 babies born each year with congenital CMV. Hearing loss may occur in 10% to 15% due to the inapparent infections, which may have a late or progressive onset. Suresh Boppana, M.D, coprincipal investigator of the study, said "that a screening test needs to have a sensitivity of at least 95%" and therefore the 30-40 percent achieved on the dried blood meant more than half the infection would have been overlooked. A new study is in progress to test RT-PCR screening of saliva, which is known to be full of viruses in babies with congenital CMV. The saliva examination is noninvasive and needs minimal processing.

Related Links:

National Institute on Deafness and Other Communication Disorders
University of Alabama at Birmingham Hospital




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.